---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-024422"
form_type: "8-K"
ticker: "ANIX"
cik: "0000715446"
company_name: "Anixa Biosciences Inc"
filed_at: "2021-10-04T23:59:59+00:00"
generated_at: "2026-06-28T23:36:54.799207+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Anixa Biosciences begins patient recruitment for Phase I breast cancer vaccine trial

## Summary
- Patient recruitment commenced Oct 1, 2021 for a preventative breast cancer vaccine developed with Cleveland Clinic and DoD.
- Phase I open-label, dose-escalation trial in triple-negative breast cancer patients at high risk of recurrence.
- Estimated 18–24 participants; trial expected to take approximately one year to complete.
- Vaccine targets alpha-lactalbumin; details at ClinicalTrials.gov identifier NCT04674306.

## SEC filing metadata
- accession: 0001493152-21-024422
- form_type: 8-K
- ticker: ANIX
- cik: 0000715446
- company_name: Anixa Biosciences Inc
- filed_at: 2021-10-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/715446/000149315221024422/0001493152-21-024422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/715446/000149315221024422/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-024422
- JSON: https://secwatch.observer/filing/0001493152-21-024422.json
- Plain text: https://secwatch.observer/filing/0001493152-21-024422.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.